Zolpidem
SIGMA/Z103 - ≥98% (HPLC), solid
Synonym: N,N,6-
CAS Number: 82626-48-0
Empirical Formula (Hill Notation): C19H21N3O
Molecular Weight: 307.39
MDL Number: MFCD00153885
Linear Formula: C19H21N3O
Product Type: Chemical
assay | ≥98% (HPLC) |
color | white |
drug control | USDEA Schedule IV; Home Office Schedule 4.1; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal) |
form | solid |
InChI | 1S/C19H21N3O/c1-13-5-8-15 |
InChI key | ZAFYATHCZYHLPB-UHFFFAOYSA |
originator | Sanofi Aventis |
Quality Level | 100 ![]() |
SMILES string | CC1=CN2C(C=C1)=NC(C3=CC=C |
solubility | 45% (w/v) aq 2-hydroxypropyl-β-cyclode |
dilute aqueous base: insoluble | |
DMSO: >10 mg/mL | |
ethanol: 50 mg/mL | |
H2O: insoluble | |
methanol: 50 mg/mL |
Biochem/physiol Actions: | Potent and selective agonist for the benzodiazepine receptor associated with the GABAA receptor; hypnotic. |
Features and Benefits: | This compound is a featured product for Neuroscience research. Click here ![]() ![]() |
Features and Benefits: | This compound is featured on the GABAA Receptors ![]() ![]() |
Features and Benefits: | This compound was developed by Sanofi Aventis ![]() ![]() |
Symbol | ![]() ![]() |
Signal word | Warning |
Hazard statements | H302 - H336 - H411 |
Precautionary statements | P261 - P264 - P270 - P271 - P273 - P301 + P312 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC) |
UNSPSC | 12352200 |